Continuous Low-Dose Lenalidomide Safe in Healthy People in Trial
STAR-LLD, an investigational continuous delivery of low doses of lenalidomide into the blood — being developed as a new treatment option for multiple…
News
Teclistamab Plus Darzalex Found to Ease Cancer Burden in Phase 1 Trial
A combination of the investigational therapy teclistamab and the approved medication Darzalex (daratumumab) reduced the cancer burden for most people with relapsed or refractory…
Nexpovio Triple Combo Approved as Myeloma Treatment in Europe
The European Commission has granted full approval to a triple combination therapy of Nexpovio (selinexor) — sold in the U.S. as Xpovio —  to treat…
Tecvayli Recommended for Conditional Approval in Europe
A branch of the European Medicines Agency (EMA) has recommended that Janssen’s investigational therapy Tecvayli (teclistamab) be granted conditional marketing authorization for adults with…
Pepaxti Combo Favored to Treat Advanced Multiple Myeloma in EU
Oncopeptides received a positive opinion from an arm of the European Medicines Agency (EMA) that is expected to take the company one step closer…
List of Rare Diseases Tops 10,000 – and Is Growing – New Analysis Finds
Note: This story was updated July 13, 2022, to correct the name of Rare-X’s CEO Charlene Son Rigby. Nonprofits, scientists, governmental organizations, and…
Talquetamab Named a Breakthrough Therapy for Hard-to-treat Myeloma
Talquetamab, a first-in-class antibody treatment being developed by Janssen Research & Development, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA)…
1st CAR T-Cell Therapy in China for Myeloma Now Under Review
The China National Medical Products Administration (NMPA) has agreed to review an application for Equecabtagene autoleucel — the country’s first chimeric antigen receptor (CAR) T-cell…
Novel Immunotherapy QXL138AM Wins Orphan Drug Status in US
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Nammi Therapeutics’ lead immunotherapy candidate QXL138AM for multiple myeloma. The…
CYT-338 Shows Anticancer Activity in Preclinical Tests
CYT-338, an investigational myeloma therapy designed to simultaneously bind to cancer cells and activate immune cells called natural killer cells, has shown promising anti-cancer…
